Verastem Oncology Reports Preliminary Q4 and 2025 Revenue, Outlines 2026 Strategic Priorities for Novel Portfolio Targeting RAS/MAPK Pathway-Driven Cancers

Verastem Oncology reported preliminary Q4 and full-year 2025 net product revenues for AVMAPKI FAKZYNJA CO-PACK of $17.5 million and $30.9 million, respectively. The company also announced the exercise of outstanding cash warrants, netting $29.4 million, and expects its cash runway to extend into the first half of 2027. In 2026, Verastem will focus on maximizing the commercial launch of AVMAPKI FAKZYNJA CO-PACK and advancing its pipeline targeting RAS/MAPK pathway-driven cancers.